Sponsor

Clinical trials sponsored by Amgen

Active studies whose public registry record names Amgen as lead sponsor.

14active studies

9recruiting now

16countries represented

783largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Atherosclerotic Cardiovascular Disease, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia783 locations

AmgenSponsor

Updated 2026-09-03 · NCT07037433See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection FractionCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Australia628 locations

AmgenSponsor

Updated 2026-07-02 · NCT07037459See eligibility →

Recruiting nowPhase 1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Cardiometabolic DiseaseCondition

AMG 513, PlaceboTreatment

United States10 locations

AmgenSponsor

Updated 2026-06-22 · NCT06585462See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Overweight, ObesityCondition

COC, Maridebart CafraglutideTreatment

United States2 locations

AmgenSponsor

Updated 2026-07-20 · NCT07523711See eligibility →

Active, not recruitingPhase 1

Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Overweight, ObesityCondition

Maridebart Cafraglutide, MoxifloxacinTreatment

United States2 locations

AmgenSponsor

Updated 2026-01-23 · NCT07229157See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Obesity DiseaseCondition

Maridebart cafraglutide, PlaceboTreatment

Japan30 locations

AmgenSponsor

Updated 2025-12-17 · NCT06987695See eligibility →

Active, not recruitingPhase 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

ObesityCondition

Maridebart Cafraglutide, PlaceboTreatment

Argentina, Australia243 locations

AmgenSponsor

Updated 2025-10-20 · NCT06858839See eligibility →

Related sponsors

Novo Nordisk A/S71 Eli Lilly and Company67 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.